- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01676636
Delivery Vehicles for Prenatal Calcium Supplementation
14. april 2021 opdateret af: Stanley Zlotkin, The Hospital for Sick Children
Preference, Acceptability, and Palatability of Alternative Delivery Vehicles for Prenatal Calcium Supplementation Among Pregnant Women in Bangladesh
The SickKids-led research team is currently developing a prenatal micronutrient powder that will contain calcium, iron, and folic acid with different absorption characteristics.
Once the powder is developed, it can be incorporated into various oral delivery vehicles.
The overall effectiveness of a micronutrient program is highly dependent on the acceptance and regular consumption of supplements (i.e., adherence) by the targeted users.
This is a study of the preference, acceptability, and palatability of 4 alternative delivery vehicles for the innovative prenatal multiple micronutrient supplement: traditional tablets, oral disintegrating tablets, unflavoured powder with a suspension agent, and flavoured powder with a suspension agent.
This study will be conducted in Dhaka, Bangladesh.
This study hypothesizes that that the formulation of the delivery vehicle will impact preference, acceptability, and palatability.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
149
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Dhaka, Bangladesh
- International Center for Diarrheal Disease Research
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 40 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Kvinde
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Women who are between 13 and 30 weeks pregnant.
Participants will be recruited from Shimantik .
Beskrivelse
Inclusion Criteria:
- Pregnant women ages 18 to < 40 years
- Gestational age of 13-30 completed weeks, estimated based on the recalled first day of the last menstrual period (LMP)
- Current residence in Dhaka at a fixed address
- Plan to remain in Dhaka for the duration of the study
Exclusion Criteria:
- Reported complications of current pregnancy
- Complicated medical or obstetric history that may increase the risk of preterm birth or prenatal complications, based on self-report
- Moderate or severe anaemia (hemoglobin < 90 g/L, accessed with Hemocue)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Pregnant Women
Women who are 13 to 30 weeks pregnant.
Each participant will take all 4 different calcium vehicles and decide which one they prefer.
|
The traditional tablets will be swallowed with liquid.
Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal.
Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
Chewable tablets are chewed in the absence of additional water.
Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day.
Participants will be asked to consume the chewable tablets with a meal.
The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing.
Appropriate foods for mixing with the powder will be at the discretion of the participants.
This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy.
A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal.
This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy.
Similar products include oral rehydration salts or artificial juice flavour crystals.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of Consumption of the Calcium Vehicle
Tidsramme: Change from Baseline in Consumption of the Calcium Vehicle at day 22
|
Consumption of the delivery vehicles will be measured during the once-weekly interactions with the research assistants in two ways: (1) by self-report from study participants; and (2) by counting the number of missing doses from those provided in the weekly supply.
|
Change from Baseline in Consumption of the Calcium Vehicle at day 22
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acceptability
Tidsramme: Day 1, Day 9, Day 16, Day 22
|
Measured by colour, preparation, administration.
|
Day 1, Day 9, Day 16, Day 22
|
|
Ease of Use
Tidsramme: Day 1, Day 9, Day 16, Day 22
|
Measured by size and ease of swallowing.
|
Day 1, Day 9, Day 16, Day 22
|
|
Patibility
Tidsramme: Day 1, Day 9, Day 16, Day 22
|
Measured by taste, texture, aftertaste, and odour.
|
Day 1, Day 9, Day 16, Day 22
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Daniel Roth, MD, The Hospital for Sick Children
- Ledende efterforsker: Stanley Zlotkin, MD, The Hospital for Sick Children
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. oktober 2012
Primær færdiggørelse (Faktiske)
1. marts 2013
Studieafslutning (Faktiske)
1. marts 2013
Datoer for studieregistrering
Først indsendt
16. august 2012
Først indsendt, der opfyldte QC-kriterier
30. august 2012
Først opslået (Skøn)
31. august 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
19. april 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. april 2021
Sidst verificeret
1. april 2021
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- 1000032744
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Graviditet
-
King's College Hospital NHS TrustEuropean Association for the Study of the LiverRekrutteringCirrhose, lever | HELLP syndrom | Intrahepatisk kolestase af graviditet | Graviditetssygdom | AFLP - Acute Fatty Lever of PregnancyDet Forenede Kongerige
Kliniske forsøg med Traditional Tablet
-
Boston UniversityNational Center for Research Resources (NCRR)Afsluttet
-
University of PittsburghRobert C. Atkins FoundationAfsluttet
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationAfsluttet
-
SanofiAfsluttet
-
Memorial Sloan Kettering Cancer CenterComprehensive Cancer Centre The NetherlandsRekrutteringKræft | Dermatologiske tilstandeForenede Stater